PolarityTE (PTE) Stock Price, News & Analysis

Company Overview

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.20 to $0.57
• 52-Week Range: N/A
• Volume: 8.50 million shs
• Average Volume: 249,591 shs
• Market Capitalization: $1.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTE Stock Analysis - Frequently Asked Questions

How were PolarityTE's earnings last quarter?

PolarityTE, Inc. (NASDAQ:PTE) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($2.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.00) by $0.75. The firm had revenue of $1.12 million for the quarter, compared to analysts' expectations of $0.97 million.

When did PolarityTE's stock split?

Shares of PolarityTE reverse split before market open on Tuesday, May 17th 2022.The 1-25 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of PolarityTE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PolarityTE investors own include Bionano Genomics (BNGO), Acasti Pharma (ACST), T2 Biosystems (TTOO), SNDL (SNDL), Zomedica (ZOM), Tonix Pharmaceuticals (TNXP) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PTE
• CIK: 1076682
• Web: www.polarityte.com
• Phone: (800) 560-3983
• Fax: 302-636-5454
• Employees: 42
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): ($3.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.83 million
• Net Margins: N/A
• Pretax Margin: -11,376.71%
• Return on Equity: -106.08%
• Return on Assets: -76.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.11
• Quick Ratio: 4.11

Sales & Book Value

• Annual Sales: $810 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.30 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,380,000
• Free Float: 6,978,000
• Market Cap: $1.78 million
• Optionable: Optionable
• Beta: 1.15